Oxy, as it is known, has not said anything
specific about selling Astenbeck or Phibro, which does some of
its proprietary trading, mainly in crude oil and select
commodities such as natural gas, platinum and corn.
But speculation is growing that the Los Angeles-based global oil
company was preparing to divest some or all of its stake in the
two after volatile, and often negative, returns from Hall, who
runs both units.
"Everything else being equal, a more profitable Astenbeck is
certainly a useful backdrop for Oxy in any negotiations with
buyers," said Pavel Molchanov, an analyst who follows Occidental
for New York's Raymond James Financial.
"If Oxy decides to sell this business after all, it will
certainly get a more fair-market value."
Hall's Astenbeck Capital Management, which manages about $3.6
billion and mostly trades long-dated U.S. and UK oil contracts,
told its investors in a note seen by Reuters on Friday that it
was up 5.4 percent on the year after posting a 7.7 percent gain
in February.
The fund did not respond to requests for comment.
Last month's gain was the highest for the hedge fund since
October 2011. Previously, Astenbeck was down 2 percent in
January after finishing 2013 with a loss of 8.3 percent.
February's gain came as U.S. oil prices jumped 5 percent on the
month after a brutal winter triggered a jump in demand for
heating fuel.
The front-month contract in U.S. oil returned to above $100 a
barrel in February, the first time since October.
Hall launched Astenbeck as a Phibro subsidiary in 2007. Oxy
bought Phibro from Citigroup for $370 million in 2009 but owns
only 20 percent of Astenbeck. Hall owns the remaining 80
percent.
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|